Rahul arora, Indian business analyst

India Medtronic Private Limited, a wholly owned subsidiary of (NYSE: MDT), today announced the launch of the Percept™ PC Deep Brain Stimulation (DBS) system.The system enabled with BrainSense™ technology is designed to capture brain signals while simultaneously delivering therapeutic stimulation, inside and outside the clinic. Ergonomically designed, the Percept PC device offers enhanced comfort and is indicated for patients with Parkinson's disease, tremor, dystonia, and epilepsy.In 2016, it was estimated that 6.1 million people worldwide had Parkinson's disease. The prevalence in India was estimated to be 10% of the global burden, that is, 5.8 lakhs.1 Parkinson's disease is a progressive disorder that eventually causes severe disability due to the increasing severity of treatmentresistant motor problems and nonmotor symptoms.Overall, movement disorders constitute 3-8% of neurological disorders in India with a crude prevalence rate (CPR) varying from 31 to 45/100,000 above 60 years of age.2DBS therapy for movement disorders has gained acceptance and widespread clinical use in recent years. DBS is an individualized therapy delivered from a small pacemaker-like device, placed under the skin of the chest or abdomen, to send electrical signals through very thin wires (leads) to a targeted area in the brain related to the symptoms of a neurological disorder."Medtronic has always been committed to changing the standard of care and improving patient outcomes. With Percept PC, physicians can now track patient brain signals and correlate these with patient-recorded actions or experiences such as symptoms, side-effects, or medication intake. This allows for more personalized, data-driven neurostimulation treatment. Medtronic is working towards devising meaningful innovations that harness the power of data to improve overall care and efficiency," said Rahul Arora, head of Neurosciences Therapy, Medtronic India.In addition to BrainSense technology, the Percept PC DBS system features several leading-edge innovations, including:The only DBS system eligible for 3T and 1.5T full-body MRI scans, providing patients access to cutting-edge medical imaging.Smart battery for personalized prediction of remaining battery life providing elevated peace of mind while planning for device replacement.Improved battery longevity compared to Medtronic's Activa™ PC neurostimulator (when using similar settings and functionality) in a smaller (reduced volume), ergonomic design for patient comfort.Low pulse width (duration of the pulse), providing expanded stimulation options.Enhanced Patient Programmer leveraging a user-friendly, custom-configured Samsung mobile device that allows patients to manage their therapy easily.Designed to facilitate expanded capabilities in the future via software upgrades - to prepare for what's next in DBS.The first Level I randomized controlled trial of Medtronic DBS Therapy for Parkinson's disease-indicated DBS (subthalamic nucleus target) patients with recent onset of motor complications achieved a 20% statistically significant improvement in time with good mobility and no troublesome dyskinesia (2.1 hours from baseline) compared to 2% (0.2 hours) with best medical therapy (BMT) alone at 24-month follow-up3.This story is provided by BusinessWire India.will not be responsible in any way for the content of this article. (ANI/BusinessWire India)( With inputs from ANI )Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Rahul AroraFOLLOW

Rahul arora, Latest News

GCCs in India have exhibited the fastest growth among all industry segments active in India's office leasing landscape. They now occupy more than 202 million sq. ft of office space across the top six cities (Bengaluru, Chennai, Delhi NCR, Hyderabad, ...

Startups are fuelling India's next wave of growth, ushering in an era of unparalleled change and innovation. Flourishing at an impressive pace, the Indian startup ecosystem is globally the third largest. Over the last few years, startups have also be ...

With over 6.97 million sq ft of space leased to startups in the first half of 2022, the industry ... ...

Medtronic Private Limited, a wholly-owned subsidiary of Medtronic plc, today announced the launch of SenSight™ directional lead system for Deep Brain Stimulation (DBS) therapy as treatment of symptoms associated with movement disorders and epilepsy. ...

India Medtronic Private Limited, a wholly-owned subsidiary of Medtronic plc (NYSE:MDT) -- a global leader in healthcare technology, today announced the launch of CE marked fourth-generation flow diverter, PipelineTM Vantage with Shield TechnologyTM f ...

Mumbai, May 19 California-based Cyber security company Trellix on Thursday announced the opening of a new data centre ... ...

India Medtronic Private Limited, a wholly owned subsidiary of Medtronic plc (NYSE: MDT) -- a global leader in healthcare technology, today announced the first clinical procedure in India with the Intellis™ spinal cord stimulation (SCS) platform, the ...

India Medtronic Private Limited, a wholly owned subsidiary of Medtronic plc (NYSE: MDT), today announced the launch of the Percept™ PC Deep Brain Stimulation (DBS) system. ...